Iopamiro 370 is applied in clinical settings that involve assessing conditions where symptoms relate to structural issues, helping to provide diagnostic clarity to physicians. This contrast agent is commonly used to support visualization of anatomical features during medical imaging and may assist in guiding the management of the underlying conditions.

The use of this agent is relevant for examining structures in various therapeutic domains. These include the assessment of vascular issues (like stenosis or aneurysms), internal organ pathologies (such as masses or lesions in the liver or kidneys), neurological abnormalities, and the structures of the urinary system.

Core Benefit: Supporting the Diagnostic Process

Iopamiro 370 is commonly used to help distinguish structural pathology, which assists in supporting therapeutic planning. For high-risk individuals, including those with mild kidney issues, the low-osmolar formulation generally supports stability when symptoms create noticeable physiological strain during complex procedures.

“The agent’s capacity to reveal anatomical detail is considered relevant when symptoms suggest a need for significant intervention.”

This specialized product is applied in scenarios requiring high-contrast visualization for unique patient groups, such as adults needing cerebral or coronary angiography, and pediatric patients undergoing specialized examinations like urography. This provides the detailed, reliable contrast that helps in the assessment of structural conditions in delicate systems.

Quick Fact:	Relief for Diagnostic Uncertainty
Primary Benefit	Provides support that helps ease the overall symptom load by clarifying their underlying structural cause.
Target Symptoms	Symptoms related to physical discomfort and systemic imbalance that point to internal masses, vascular blockages, or neurological abnormalities.

Eligibility for Iopamiro 370: Official Regulatory Status

Iopamiro 370 (Iopamidol) is an officially approved radiopaque diagnostic agent for use in Adults and Pediatric Patients across multiple labeled indications, including angiography and urography. The eligibility for this medicine is strictly defined by regulatory authorities.

Classification	Population/Condition	Restriction Type
Contraindicated Use	Hypersensitivity to Iopamidol or excipients	Absolute Prohibition
	Intrathecal Administration	Prohibited Use by Route
	Immediate Repeat Myelography	Procedural Prohibition
Conditional Use	Severe renal or hepatic impairment	Requires Special Precautions
	Multiple Myeloma / Paraproteinemia	Requires Special Precautions
	Homocystinuria (for angiography)	Use Should Be Avoided

Age-Related Eligibility: Use is established for neonates and older children, with a specific regulatory warning noting the risk of transient thyroid dysfunction in pediatric patients 0 to 3 years of age. Use in older adults is generally permitted, though caution is required in those with pre-existing organ impairment.

Pregnancy and Lactation: Use during pregnancy is typically restricted to instances where the expected diagnostic benefit clearly outweighs the potential risk. Caution should be exercised when administering Iopamidol to women who are breastfeeding, as advised by the manufacturer.

---

Official Eligibility Statements:

• Contraindicated in patients with known hypersensitivity to the drug or its components.
• Approved for use in pediatric and adult populations for specified intravascular diagnostic procedures.
• Use is strictly prohibited via the intrathecal route for this formulation.

Connection to the overall eligibility profile: Regulatory documentation structures the use of Iopamiro 370 by establishing absolute contraindications, such as known drug allergy, and prohibiting the unauthorized intrathecal route of administration. Eligibility is conditionally defined for patients with severe pre-existing organ impairment or specific metabolic disorders, requiring special precautions before administration is allowed. This framework defines who can use the medicine only under precise, labeled conditions.

Interactions with Other Medicines and Products

The official regulatory profile for Iopamiro 370 highlights the need for careful management when used with several medicinal product categories due to the potential for clinically significant interactions.

---

Documented Interacting Substances

• Biguanides (e.g., Metformin): Administration of this contrast agent may lead to transient renal dysfunction, which can enhance the risk of Metformin-associated lactic acidosis in diabetic patients with pre-existing renal impairment. Specific protocols require Metformin to be stopped 48 hours prior to the procedure and only restarted 48 hours afterward if kidney function is stable.
• Beta-Blockers and Interleukin Agents (e.g., Aldesleukin): These medicines elevate the risk of more severe anaphylactoid reactions to the contrast medium, and beta-blockers may impair the effectiveness of treatment for bronchospasm.
• Vasopressors: Use with vasopressors strongly potentiates the neurological effects of the intra-arterial contrast medium.
• Iobenguane I 123/I 131: Iopamidol increases the systemic levels of this radiopharmaceutical by decreasing its renal clearance.
• Radioactive Iodine (^131 I and ^123 I): The iodine content of the contrast agent temporarily interferes with the thyroid uptake of radioactive iodine, which can decrease the efficacy of diagnostic or therapeutic use for up to eight weeks.
• Intrathecal Corticosteroids: The concomitant intrathecal (spinal) administration of corticosteroids is contraindicated.

---

Procedural Restriction

It is strictly required that no other drugs or contrast media be mixed with the Iopamiro 370 solution or injected through the same intravenous line due to potential chemical incompatibility.

How Iopamiro 370 Works: Mechanism of Action

Iopamiro 370 functions through a physical-chemical interaction with radiation, rather than conventional pharmacological action on biological receptors or enzymes. The drug's mechanism is defined by three key domains.

First, X-ray Attenuation for Contrast Enhancement occurs because the active ingredient, Iopamidol, contains dense iodine atoms. These atoms cause a strong attenuation (blocking) of X-ray photons, significantly greater than surrounding soft tissues. This results in radiopacity, the temporary physiological effect of making internal structures visible on an image detector.

Second, the Systemic Distribution and Extracellular Confinement defines the agent's path. As a non-ionic compound, it rapidly distributes unchanged throughout the bloodstream and the extracellular fluid space. Its size and properties prevent it from passively crossing the intact blood-brain barrier (BBB) or cell membranes, allowing it to temporarily outline the body's vascular and interstitial compartments.

Third, Passive Renal Filtration and Clearance governs its elimination. Since Iopamiro 370 is biologically inert and not metabolized, its systemic action concludes with rapid, passive glomerular filtration by the kidneys and excretion into the urine. This process causes temporary opacification of the renal collecting system and dictates the short duration of the drug’s systemic physiological consequences.

Iopamiro 370 (iopamidol injection) is a radiopaque contrast agent administered exclusively via the intra-arterial or intravenous route for diagnostic imaging procedures; it is NOT FOR INTRATHECAL USE.

Administration and Preparation

• Preparation: Visually inspect the solution for particulate matter or discoloration before use. The solution may be administered at body temperature (37°C or 98.6°F) or room temperature (20°C to 25°C or 68°F to 77°F). Do not mix Iopamiro with other drugs or nutritional admixtures. Single-dose containers must be used for one procedure only, and any unused portion must be discarded.
• Hydration: Patients must be well hydrated prior to and following the administration of the contrast agent to minimize risk, especially in patients with impaired renal function.
• Technique: Aseptic technique is mandatory for all handling. When administered intra-arterially, meticulous technique (including frequent catheter flushing with heparinized saline) must be used to minimize the risk of thromboembolic events.

Dosing and Schedule

• Dosing: Dosage must be individualized based on the specific procedure, patient's age, body weight, cardiac function, and renal status. The lowest dose necessary to achieve adequate visualization should be utilized. Example adult intravenous doses for Iopamiro 370 include 40 mL for excretory urography and 80 mL to 160 mL for Contrast-Enhanced Computed Tomography (CECT) of the body.
• Pediatric Use: For pediatric angiocardiography, the maximum cumulative dose is leq 5 mL/kg for neonates and leq 8 mL/kg for children aged four weeks and older. Dosage limitations by age group must be strictly followed.
• Frequency: This is a single-procedure agent, and no missed-dose rules apply. Administration is timed for the immediate execution of the diagnostic imaging study.

Research Evidence / Overview of Studies for Iopamiro 370

---

Evidence for Use in Complex Vascular and Cardiac Imaging

Research has primarily examined Iopamiro 370 in short-term studies, including trials alongside other contrast agents. The main focus of this research was studied for metrics related to visualization parameters, such as Contrast-to-Noise Ratio (CNR) and the measurement of vessel anatomy detail. Findings describe patterns observed in the studies where research evaluated the use of Iopamiro 370, measured levels of tissue density, particularly in the coronary arteries. Comparative findings varied; some research evaluated whether imaging outcomes were similar to those of other low-osmolar agents, while other studies described different patterns in physiological responses regarding patient-reported outcomes related to physical discomfort.

Evidence for Use in Contrast-Enhanced Computed Tomography (CECT)

Regulatory and comparative trials research examined how Iopamiro 370 influences tissue density in adult and pediatric patients referred for CECT of the head, chest, and abdomen. The main study outcomes examined were the level of tissue opacification achieved (measured in Hounsfield Units) and the overall visualization needed for accurate lesion detection. Research monitored kidney function markers after CECT in populations with co-existing conditions, such as diabetes and chronic kidney factors. Data show patterns related to its formulation, where tissue density opacification was observed in a dose-dependent manner, peaking at defined short time intervals after injection.

---

Follow-up Duration and Unresolved Research Questions

Contrast agents are typically researched based on their immediate ability to enhance diagnostic images. Due to this focus, the follow-up durations were limited across the core regulatory trials for Iopamiro 370. This means that long-term effects are not fully established, and there is limited information for long-term outcomes regarding patient status after the procedure. The main questions that remain uncertain are primarily focused on extended patient health. Research is ongoing regarding the full context of contrast media use in patients with advanced kidney impairment.

Common questions about Iopamiro 370 (FAQ)

Q: Is Iopamiro 370 a radioactive contrast agent?

Iopamiro 370 is not a radioactive agent. Official product information classifies it as an iodinated, radiopaque contrast agent. Its function involves a physical process where the dense iodine content blocks X-rays to create an image, a mechanism distinct from nuclear medicine or radioactive agents.

Q: Is Iopamiro 370 similar to other contrast dyes I've had before?

Iopamiro (Iopamidol) belongs to a class of contrast media known as non-ionic agents. This classification is described in official documentation as a feature associated with improved physiological tolerance compared to older, higher-osmolar ionic contrast compounds.

Q: How long does Iopamiro 370 stay in your system?

According to regulatory pharmacokinetics data, the drug’s action is of short duration. For patients with normal kidney function, the plasma half-life is approximately two hours. The majority of the dose (over 90%) is typically eliminated from the body via renal clearance within 72 to 96 hours (three to four days) of administration.

Q: Can people with a history of heart issues receive Iopamiro 370?

Official safety information identifies patients with certain heart issues, such as congestive heart failure and severe cardiac diseases, as having an increased potential risk for cardiovascular adverse reactions. Official safety guidance recommends close patient monitoring and other special precautions when the contrast agent is used in these populations.

Q: Why do patients sometimes feel a warming sensation after receiving Iopamiro 370?

The sensation of warmth or flushing throughout the body is listed in official product information as a common and expected physiological effect of receiving this contrast agent. This reaction is known to be transient and is often related to the rapid administration into the bloodstream.

Q: Are there different concentrations of Iopamiro?

Yes, the active ingredient in Iopamiro 370, which is Iopamidol, is generally available in several different concentrations. The concentration is typically labeled as the amount of iodine per millimeter, with examples including 200, 250, 300, and 370 mg I/mL of iodine content.

Q: How long do the common side effects of Iopamiro 370 last?

Common side effects, such as nausea or headache, are generally described in official information as transient (short-lasting). While the drug itself is eliminated within 72 to 96 hours, a specific guaranteed duration for the common symptoms is not provided, as individual patient experiences may vary.

Q: What measures are taken to prevent reactions to Iopamiro 370?

Preventing reactions involves assessing the patient’s history for prior allergies or previous contrast medium reactions. Official guidance states that premedication (such as antihistamines or corticosteroids) may be administered to high-risk patients, though this may only reduce the incidence and severity of reactions.

Q: What type of doctor administers Iopamiro 370?

Iopamiro 370 is a diagnostic agent that requires administration under the direct supervision of a qualified physician, such as a radiologist or cardiologist, or another licensed practitioner. This supervision is required to ensure the procedure adheres to the facility’s protocol and regulatory standards.

Q: Can Iopamiro 370 interfere with blood test results?

Yes, official documents state that the iodine content of Iopamiro 370 can interfere with the results of certain laboratory tests. One example is the protein-bound iodine test, and healthcare providers are informed of this potential interference when evaluating lab results shortly after the procedure.

Q: Do people with asthma have a higher risk with Iopamiro 370?

Regulatory documents indicate that patients with a history of allergic disorders, which includes conditions like bronchial asthma, have an increased potential risk of developing hypersensitivity reactions when receiving this contrast agent.

The storage and disposal of Iopamiro 370 must follow strict regulatory guidelines to maintain product integrity and ensure safety.

Official Storage Conditions

Requirement	Details (Based on Regulatory Labeling)
Storage Temperature	Store at Controlled Room Temperature (20 C to 25 C or 68 F to 77 F).
Prohibited Conditions	Do not freeze the solution; discard immediately if crystallization or particulates are observed.
Protection	Must be protected from light and stored in the original container.
Pre-Use Handling	Visually inspect for discoloration; the solution may be warmed to body temperature before administration.
Child Safety	Keep this product out of the sight and reach of children.

Disposal Requirements

The container is for single use only, and any unused portion of the solution must be discarded immediately after the procedure. All unused or expired product must be disposed of in accordance with local regulations for pharmaceutical waste, with a mandatory instruction not to allow the product to enter sewers or surface/ground water.